Clinical Trial Update: MK-3475 as Maintenance Therapy in Extensive Stage SCLC [Phase 2]

View source ↗

Summary

Phase 2 trial updates maintenance therapy MK-3475 (pembrolizumab) in extensive stage small cell lung carcinoma with completed results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Carcinoma

Drugs mentioned

• MK-3475 (pembrolizumab)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-10-26